Which fungal infection would likely have a negative serum (1,3)-beta-D-glucan assay, invasive aspergillosis, invasive candidiasis, pneumocystic jirovecii infection, or mucormycosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Serum (1,3)-Beta-D-Glucan Assay in Fungal Infections

Mucormycosis is the only fungal infection among those listed that would have a negative serum (1,3)-beta-D-glucan assay result. 1, 2

Diagnostic Value of (1,3)-Beta-D-Glucan Testing

Mechanism and Coverage

  • (1,3)-Beta-D-glucan is a cell wall component found in most pathogenic fungi, but with notable exceptions:
    • Present in: Aspergillus, Candida, and Pneumocystis jirovecii 3, 4
    • Absent in: Mucorales (the causative agents of mucormycosis) and Cryptococcus neoformans 3

Specific Fungal Infections and BDG Results

Mucormycosis

  • The cell wall of Mucorales fungi lacks significant amounts of (1,3)-beta-D-glucan 1
  • In vitro analysis of culture supernatants from different Mucorales species showed low antigen reactivity compared to other molds 1
  • Multiple studies have confirmed negative (1,3)-beta-D-glucan results in patients with mucormycosis 1, 2
  • The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and European Confederation of Medical Mycology (ECMM) guidelines explicitly state that "(1,3)-beta-D-glucan is a common component of the cell wall of a wide variety of fungi but not of the Mucorales" 1
  • The guidelines rate (1,3)-beta-D-glucan testing as "D" level recommendation (not recommended) for mucormycosis diagnosis 1

Invasive Aspergillosis

  • (1,3)-Beta-D-glucan is present in the cell wall of Aspergillus species 3
  • BDG testing appears to be more sensitive than galactomannan detection in patients with invasive aspergillosis 3
  • Median initial BDG values in invasive aspergillosis are typically >500 pg/mL 4

Invasive Candidiasis

  • Candida species contain (1,3)-beta-D-glucan in their cell walls 3, 4
  • BDG testing has approximately 81% sensitivity for invasive candidiasis 2
  • Median initial BDG values in invasive candidiasis are typically around 136 pg/mL 4

Pneumocystis jirovecii Infection

  • Pneumocystis jirovecii contains significant amounts of (1,3)-beta-D-glucan 3
  • BDG testing is highly sensitive for Pneumocystis pneumonia 4
  • Median initial BDG values in PCP are typically >500 pg/mL 4

Clinical Implications and Diagnostic Approach

  • When evaluating a patient with suspected invasive fungal infection and negative BDG test:

    • Consider mucormycosis, especially if galactomannan tests are also negative but radiological findings suggest invasive fungal disease 1, 2
    • Direct microscopy, culture, and histopathology remain the primary diagnostic methods for mucormycosis 1, 2
  • False positives can occur with:

    • Hemodialysis with cellulose membranes
    • Treatment with immunoglobulin or albumin
    • Blood products filtered through cellulose filters
    • Certain intravenous antimicrobials 3, 5

Summary

Among invasive aspergillosis, invasive candidiasis, Pneumocystis jirovecii infection, and mucormycosis, only mucormycosis would consistently yield a negative serum (1,3)-beta-D-glucan assay result due to the absence of this cell wall component in Mucorales fungi.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Invasive Fungal Infections Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Post-diagnostic kinetics of the (1 → 3)-β-D-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2012

Research

Diagnostic performance of the (1-->3)-beta-D-glucan assay for invasive fungal disease.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.